SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma

Oncotarget. 2017 Jul 4;8(27):43953-43966. doi: 10.18632/oncotarget.16693.

Abstract

SNORD47 is a member of the C/D box small nucleolar RNAs, which have been implicated in cancer development. We intended to investigate the therapeutic potential of SNORD47 in glioma. We found that the expression of SNORD47 was downregulated in glioma tissues samples and inversely associated with advanced tumor stage (WHO grade IV). Kaplan-Meier survival analysis revealed that glioma patients with high SNORD47 expression had longer overall survival than those with low SNORD47 expression. SNORD47 suppressed the proliferation of glioma cells and induced G2 phase arrest. In addition, upregulation of SNORD47 suppressed invasion and epithelial-mesenchymal transition in glioma cells, and combination treatment with lenti-SNORD47 could augment the anti-tumor effect of temozolomide. These results showed that SNORD47 acted as a tumor suppressor in glioma, and provided the potential anti-tumor function in glioma treatment.

Keywords: SNORD47; cell cycle; glioblastoma; invasion; proliferation.

MeSH terms

  • Adult
  • Aged
  • Animals
  • Cell Cycle / genetics
  • Cell Line, Tumor
  • Cell Movement / genetics
  • Cell Proliferation / genetics
  • Cell Transformation, Neoplastic / genetics*
  • Dacarbazine / analogs & derivatives
  • Dacarbazine / pharmacology
  • Disease Models, Animal
  • Disease Progression
  • Drug Resistance, Neoplasm / genetics
  • Female
  • G2 Phase Cell Cycle Checkpoints / genetics
  • Gene Expression Regulation, Neoplastic
  • Genes, Tumor Suppressor*
  • Glioblastoma / genetics*
  • Glioblastoma / mortality
  • Glioblastoma / pathology*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Mice
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis
  • RNA, Small Nucleolar / genetics*
  • Temozolomide
  • Tumor Burden
  • Xenograft Model Antitumor Assays

Substances

  • RNA, Small Nucleolar
  • Dacarbazine
  • Temozolomide